{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"86.2","upperLimit":"94.4","value":"90.3"},{"groupId":"OG003","lowerLimit":"90.0","upperLimit":"96.6","value":"93.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"227"},{"groupId":"OG003","value":"237"}],"units":"Participants"}],"title":"IFRT vs PFRT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.4","upperLimit":"92.6","value":"85.5"},{"groupId":"OG001","lowerLimit":"84.3","upperLimit":"96.5","value":"90.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"LDCSI vs SDCSI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"227"},{"groupId":"OG003","value":"237"}],"units":"Participants"}],"description":"OS was defined as the time interval from date of study entry to date of death from any cause or to the date of last follow-up for survivors. OS was estimated using the method of Kaplan and Meier. 3-year estimates are reported with 95% CI's. For purposes of this analysis, arms I, III and V (involved field radiation therapy \\[IFRT\\]) are combined and compared to arms II, IV and VI (posterior fossa irradiation \\[PFRT\\]).","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes eligible patients 3-7 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the LDCSI arms (Treatment Arms I or II)","id":"OG000","title":"Low-dose Craniospinal Radiation (LDSCI)"},{"description":"Includes eligible patients 3-7 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the SDCSI arms (Treatment Arms III or IV)","id":"OG001","title":"Standard-dose Craniospinal Radiation (SDCSI)"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the IFRT arms (Treatment Arms I, III, V)","id":"OG002","title":"Involved Field Radiation (IFRT)"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the PFRT arms (Treatment Arms II, IV, VI)","id":"OG003","title":"Posterior Fossa Radiation (PFRT)"}],"paramType":"NUMBER","populationDescription":"Per protocol only eligible \\& evaluable pts were included.Pts with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). 26/23 IFRT/PFRT pts were NE, leaving 227 vs 237 for this comparison. The LD/SD CSI comparison was done only in pts 3-7 yrs of age. 11/8 LD/SDCSI pts were NE, leaving 116 vs 110 for this comparison.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Probability of 3 yr OS rate"}